- Home
- SSP vs INBX Comparison
SSP vs INBX Comparison
Compare SSP & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSP
- INBX
- Stock Information
- Founded
- SSP 1878
- INBX 2010
- Country
- SSP United States
- INBX United States
- Employees
- SSP N/A
- INBX N/A
- Industry
- SSP Broadcasting
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SSP Industrials
- INBX Health Care
- Exchange
- SSP Nasdaq
- INBX Nasdaq
- Market Cap
- SSP 252.6M
- INBX 178.5M
- IPO Year
- SSP 1988
- INBX 2020
- Fundamental
- Price
- SSP $3.27
- INBX $23.50
- Analyst Decision
- SSP Buy
- INBX Hold
- Analyst Count
- SSP 2
- INBX 1
- Target Price
- SSP $6.00
- INBX N/A
- AVG Volume (30 Days)
- SSP 918.4K
- INBX 138.8K
- Earning Date
- SSP 08-07-2025
- INBX 08-12-2025
- Dividend Yield
- SSP N/A
- INBX N/A
- EPS Growth
- SSP N/A
- INBX N/A
- EPS
- SSP 0.93
- INBX 111.58
- Revenue
- SSP $2,472,701,000.00
- INBX $200,000.00
- Revenue This Year
- SSP N/A
- INBX N/A
- Revenue Next Year
- SSP $9.60
- INBX N/A
- P/E Ratio
- SSP $3.46
- INBX $0.22
- Revenue Growth
- SSP 6.28
- INBX N/A
- 52 Week Low
- SSP $1.36
- INBX $10.80
- 52 Week High
- SSP $4.17
- INBX $24.42
- Technical
- Relative Strength Index (RSI)
- SSP 49.81
- INBX 87.77
- Support Level
- SSP $2.70
- INBX $20.48
- Resistance Level
- SSP $3.84
- INBX $24.30
- Average True Range (ATR)
- SSP 0.28
- INBX 1.45
- MACD
- SSP -0.06
- INBX 0.56
- Stochastic Oscillator
- SSP 30.14
- INBX 94.04
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.